Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

This Dividend King Is Down 26%. When Will It Bounce Back?

Healthcare stocks have lagged the broader market this year as investors chased higher-growth names in tech and AI. Dividend payers, in particular, have taken a hit amid shifting rate expectations and sector-specific hiccups. That backdrop sets up an interesting opportunity for income seekers who prize consistency over flash. 

Take Abbott Laboratories (ABT). The stock sits 26% below its 52-week high of $139.06, trading near $102 per share. When will it bounce back? The short answer: the fundamentals already point higher, and the pullback looks more like a buying window than a warning sign.

Fundamentals

See More
  • Market Capitalization, $K 177,440,000
  • Shares Outstanding, K 1,741,657
  • Annual Sales, $ 44,328 M
  • Annual Income, $ 6,524 M
  • EBIT $ 9,735 M
  • EBITDA $ 12,851 M
  • 60-Month Beta 0.74
  • Price/Sales 4.09
  • Price/Cash Flow 14.88
  • Price/Book 3.43

Options Overview Details

View History
  • Implied Volatility 32.60% (-0.72%)
  • Historical Volatility 20.74%
  • IV Percentile 97%
  • IV Rank 61.22%
  • IV High 42.50% on 04/07/25
  • IV Low 16.97% on 08/12/25
  • Expected Move (DTE 2) 2.38 (2.32%)
  • Put/Call Vol Ratio 0.72
  • Today's Volume 7,333
  • Volume Avg (30-Day) 12,462
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 141,126
  • Open Int (30-Day) 160,035
  • Expected Range 100.29 to 105.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.14
  • Number of Estimates 9
  • High Estimate $1.17
  • Low Estimate $1.13
  • Prior Year $1.09
  • Growth Rate Est. (year over year) +4.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.88 +1.78%
on 03/31/26
115.85 -11.38%
on 03/02/26
-13.68 (-11.76%)
since 02/27/26
3-Month
100.88 +1.78%
on 03/31/26
129.46 -20.69%
on 01/06/26
-22.17 (-17.76%)
since 12/26/25
52-Week
100.88 +1.78%
on 03/31/26
139.06 -26.17%
on 06/24/25
-28.15 (-21.52%)
since 03/28/25

Most Recent Stories

More News
This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion,...

ABT : 102.67 (+0.78%)
JNJ : 244.44 (+0.80%)
MDT : 86.65 (+1.06%)
$INX : 6,528.52 (+2.91%)
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

ABBOTT PARK, Ill. and NEW YORK , March 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions...

ABT : 102.67 (+0.78%)
Abbott hosts conference call for first-quarter earnings

ABBOTT PARK, Ill. , March 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens.

ABT : 102.67 (+0.78%)
Abbott Earnings Preview: What to Expect

Abbott is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

ABT : 102.67 (+0.78%)
XLV : 146.61 (+1.94%)
$SPX : 6,528.52 (+2.91%)
John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

ABBOTT PARK, Ill. , March 24, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company...

ABT : 102.67 (+0.78%)
Abbott completes acquisition of Exact Sciences

ABBOTT PARK, Ill. , March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening...

ABT : 102.67 (+0.78%)
Abbott acquisition of Exact Sciences set to close on March 23, 2026

ABBOTT PARK, Ill. , March 20, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows...

ABT : 102.67 (+0.78%)
3 High Dividend Growth Kings for Generations of Income That Are Still Rated ‘Buy’

These 3 Dividend Kings combine steady businesses, rising dividends, and solid upside potential for long-term income investors.

ABT : 102.67 (+0.78%)
LOW : 236.28 (+1.59%)
RPM : 99.40 (+1.37%)
This Dividend King With a 54-Year Dividend Streak Is Down 13% YTD. Time to Buy the Dip?

This Dividend King is suddenly on sale. Should you buy the dip?

ABT : 102.67 (+0.78%)
$SPX : 6,528.52 (+2.91%)
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

ABBOTT PARK, Ill. , March 12, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using...

ABT : 102.67 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures...

See More

Key Turning Points

3rd Resistance Point 106.75
2nd Resistance Point 105.21
1st Resistance Point 103.94
Last Price 102.67
1st Support Level 101.14
2nd Support Level 99.60
3rd Support Level 98.33

See More

52-Week High 139.06
Fibonacci 61.8% 124.47
Fibonacci 50% 119.97
Fibonacci 38.2% 115.46
Last Price 102.67
52-Week Low 100.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.